BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 3397768)

  • 1. Human central nervous system and plasma pharmacology of mitoxantrone.
    Green RM; Stewart DJ; Hugenholtz H; Richard MT; Thibault M; Montpetit V
    J Neurooncol; 1988; 6(1):75-83. PubMed ID: 3397768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human autopsy tissue concentrations of mitoxantrone.
    Stewart DJ; Green RM; Mikhael NZ; Montpetit V; Thibault M; Maroun JA
    Cancer Treat Rep; 1986 Nov; 70(11):1255-61. PubMed ID: 3768871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration.
    Czejka MJ; Jäger W; Georgopoulos A; Schüller J
    Eur J Drug Metab Pharmacokinet; 1990; 15(3):219-22. PubMed ID: 2253652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of mitoxantrone. A review.
    Ehninger G; Schuler U; Proksch B; Zeller KP; Blanz J
    Clin Pharmacokinet; 1990 May; 18(5):365-80. PubMed ID: 2185907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution characteristics of mitoxantrone in a patient undergoing hemodialysis.
    Boros L; Cacek T; Pine RB; Battaglia AC
    Cancer Chemother Pharmacol; 1992; 31(1):57-60. PubMed ID: 1458559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.
    Schleyer E; Kamischke A; Kaufmann CC; Unterhalt M; Hiddemann W
    Leukemia; 1994 Mar; 8(3):435-40. PubMed ID: 8127148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration.
    Nagel JD; Varossieau FJ; Dubbelman R; ten Bokkel Huinink WW; McVie JG
    Cancer Chemother Pharmacol; 1992; 29(6):480-4. PubMed ID: 1568292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.
    Stewart DJ; Richard MT; Hugenholtz H; Dennery JM; Belanger R; Gerin-Lajoie J; Montpetit V; Nundy D; Prior J; Hopkins HS
    J Neurooncol; 1984; 2(2):133-9. PubMed ID: 6481426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).
    Savaraj N; Lu K; Feun LG; Leavens ME; Stewart D; Burgess MA; Benjamin RS; Loo TL
    J Neurooncol; 1983; 1(1):15-9. PubMed ID: 6678302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentration of vinblastine in human intracerebral tumor and other tissues.
    Stewart DJ; Lu K; Benjamin RS; Leavens ME; Luna M; Yap HY; Loo TL
    J Neurooncol; 1983; 1(2):139-44. PubMed ID: 6678966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats.
    DiMeco F; Li KW; Tyler BM; Wolf AS; Brem H; Olivi A
    J Neurosurg; 2002 Nov; 97(5):1173-8. PubMed ID: 12450040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.
    Richard B; Launay-Iliadis MC; Iliadis A; Just-Landi S; Blaise D; Stoppa AM; Viens P; Gaspard MH; Maraninchi D; Cano JP
    Br J Cancer; 1992 Mar; 65(3):399-404. PubMed ID: 1558794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
    Schwendener RA; Fiebig HH; Berger MR; Berger DP
    Cancer Chemother Pharmacol; 1991; 27(6):429-39. PubMed ID: 2013113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma.
    Hu OY; Chang SP; Law CK; Jian JM; Chen KY
    Cancer; 1992 Feb; 69(4):847-53. PubMed ID: 1735075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.
    Krukemeyer MG; Krenn V; Jakobs M; Wagner W
    J Surg Res; 2012 Jun; 175(1):35-43. PubMed ID: 21470623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration.
    Alberts DS; Surwit EA; Peng YM; McCloskey T; Rivest R; Graham V; McDonald L; Roe D
    Cancer Res; 1988 Oct; 48(20):5874-7. PubMed ID: 3167842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.
    Patel KJ; Trédan O; Tannock IF
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):127-38. PubMed ID: 23680920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain tissue concentration of mitoxantrone in the rat in relation to in vitro chemosensitivity of malignant human intracranial tumors--preliminary results.
    Tonn JC; Schönmayr R; Braun R; Kraemer HP; Ehninger G
    J Chemother; 1989 Jul; 1(4 Suppl):1181-2. PubMed ID: 16312824
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.
    Canal P; Attal M; Chatelut E; Guichard S; Huguet F; Muller C; Schlaifer D; Laurent G; Houin G; Bugat R
    Cancer Res; 1993 Oct; 53(20):4850-4. PubMed ID: 8402672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.